The purpose of this study is to demonstrate the safety and performance of the FDA-cleared Dexcom Smart Basal - a CGM-informed basal insulin calculator for people with type 2 diabetes (T2D) - when used in accordance with its intended use.

Who can Participate

1. Participants with type 2 diabetes (T2D). 2. Ages ≥ 18 years (“age” determined at the time of the Screening Visit). 3. Participants may be starting basal insulin. If participants are on insulin maintenance, participants are required to be taking basal insulin for at least one month prior to beginning Phase 1 and at least 72 hours prior to screening. 4. Comfortable with and willing to administer basal insulin injections once a day and log time and amount of each daily injections in a mobile application. 5. Willing to use a compatible smartphone with the Dexcom CGM mobile application featuring Smart Basal, and to wear and replace the Dexcom CGM as required. 6. Willing to access an internet connection and log into a Dexcom account to receive daily dose recommendations. 7. Able to speak, read, and write English

Study ID